Lionhunter Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Lionhunter Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.43M	Buy	+15,350	New	+$2.08M	1.1%	30

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Lionhunter Capital Management's XBI Position: Q2 2026 in Review

Lionhunter Capital Management opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 15,350 shares worth $2.43M. The stake represents 1.1% of the portfolio and ranks #30 among its holdings.

887 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Lionhunter Capital Management held 15,350 shares of State Street SPDR S&P Biotech ETF worth $2.43M as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Lionhunter Capital Management position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 1.1% of Lionhunter Capital Management's portfolio in Q2 2026, its #30 holding.
887 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Lionhunter Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.